Elliot Wilbur
Stock Analyst at Raymond James
(1.47)
# 2,404
Out of 4,412 analysts
42
Total ratings
31.82%
Success rate
-8.16%
Average return
Main Sectors:
13 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLGL Sol-Gel Technologies | Maintains: Strong Buy | $9 → $7 | $0.85 | +722.56% | 7 | Aug 11, 2023 | |
| ADMA ADMA Biologics | Maintains: Strong Buy | $5 → $6 | $6.55 | -8.40% | 4 | Aug 10, 2023 | |
| ANIP ANI Pharmaceuticals | Maintains: Outperform | $48 → $49 | $65.36 | -25.03% | 5 | May 9, 2023 | |
| OGN Organon & Co. | Initiates: Outperform | $33 | $18.55 | +77.90% | 1 | Mar 16, 2023 | |
| PRGO Perrigo Company | Maintains: Outperform | $42 → $43 | $31.94 | +34.63% | 5 | Mar 6, 2023 | |
| PETQ PetIQ | Maintains: Outperform | $21 → $16 | $16.53 | -3.21% | 4 | Oct 25, 2022 | |
| PYPD PolyPid | Downgrades: Outperform | $450 → $120 | $4.75 | +2,424.72% | 2 | Sep 6, 2022 | |
| VTRS Viatris | Downgrades: Market Perform | n/a | $11.57 | - | 3 | Mar 1, 2022 | |
| TEVA Teva Pharmaceutical | Downgrades: Market Perform | n/a | $13.81 | - | 2 | Oct 28, 2021 | |
| ZTS Zoetis | Downgrades: Market Perform | n/a | $158.42 | - | 4 | Jul 16, 2021 | |
| ELAN Elanco Animal Health | Initiates: Market Perform | n/a | $13.26 | - | 1 | Jan 10, 2020 | |
| DERM Journey Medical | Upgrades: Market Perform | n/a | $3.40 | - | 2 | Jan 17, 2019 | |
| AMPH Amphastar Pharmaceuticals | Downgrades: Market Perform | n/a | $41.11 | - | 2 | Nov 9, 2017 |
Sol-Gel Technologies
Aug 11, 2023
Maintains: Strong Buy
Price Target: $9 → $7
Current: $0.85
Upside: +722.56%
ADMA Biologics
Aug 10, 2023
Maintains: Strong Buy
Price Target: $5 → $6
Current: $6.55
Upside: -8.40%
ANI Pharmaceuticals
May 9, 2023
Maintains: Outperform
Price Target: $48 → $49
Current: $65.36
Upside: -25.03%
Organon & Co.
Mar 16, 2023
Initiates: Outperform
Price Target: $33
Current: $18.55
Upside: +77.90%
Perrigo Company
Mar 6, 2023
Maintains: Outperform
Price Target: $42 → $43
Current: $31.94
Upside: +34.63%
PetIQ
Oct 25, 2022
Maintains: Outperform
Price Target: $21 → $16
Current: $16.53
Upside: -3.21%
PolyPid
Sep 6, 2022
Downgrades: Outperform
Price Target: $450 → $120
Current: $4.75
Upside: +2,424.72%
Viatris
Mar 1, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $11.57
Upside: -
Teva Pharmaceutical
Oct 28, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $13.81
Upside: -
Zoetis
Jul 16, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $158.42
Upside: -
Elanco Animal Health
Jan 10, 2020
Initiates: Market Perform
Price Target: n/a
Current: $13.26
Upside: -
Journey Medical
Jan 17, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $3.40
Upside: -
Amphastar Pharmaceuticals
Nov 9, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $41.11
Upside: -